AstraZeneca Toprol Patents Are Invalid, Finds Federal Judge
This article was originally published in The Pink Sheet Daily
Executive Summary
A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.
You may also be interested in...
Latest Toprol-XL Generics See Quick Substitution Pick-Up
Recently launched 100 mg and 200 mg generic strengths capture one-third of scripts.
Latest Toprol-XL Generics See Quick Substitution Pick-Up
Recently launched 100 mg and 200 mg generic strengths capture one-third of scripts.
KV Gets ANDA Approval For Two Strengths Of AstraZeneca’s Toprol-XL
KV believes it has 180-day exclusivity for the 100 mg and 200 mg strengths of the hypertension treatment.